ONC Delivers 41% Revenue Growth, Brukinsa Takes BTKi Lead, and Free Cash Flow Hits Record Highs in Q3 2025
Financial Performance Signals Strong Operating Momentum
BeOne Medicines (NASDAQ: ONC) posted an impressive third quarter in 2025, notching a 41% year-over-year revenue increase to $1.41 billion and demonstrating substantial operational progress. The key driver was the continued global expansion of Brukinsa, which now holds the revenue lead in the BTK inhibitor (BTKi) class.
Gross margins for Q3 climbed to 85.9% (GAAP), reflecting an increased sales mix from Brukinsa and productivity gains across the portfolio. Adjusted gross margin rose even higher to 86.3%, emphasizing strong underlying profitability.
| Key Financials | Q3 2025 | Q3 2024 | % Change |
|---|---|---|---|
| Total Revenue ($M) | 1,412.3 | 1,001.6 | +41% |
| Brukinsa Revenue ($M) | 1,000 | 663 | +51% |
| GAAP Net Income ($M) | 124.8 | -121.4 | Turned Positive |
| Free Cash Flow ($M) | 354.5 | 54.7 | +548% |
| GAAP Diluted EPS/ADS | 1.09 | -1.15 | Turned Positive |
| Gross Margin (GAAP) | 85.9% | 82.8% | +310bps |
Brukinsa Emerges as BTKi Class Leader—Expansion Continues in U.S. and Europe
Brukinsa (zanubrutinib) contributed $1.0 billion in revenue during Q3, up 51% from the previous year. In the U.S., sales surged to $739 million (+47%), driven by rising patient share and demand across indications. European markets delivered even stronger momentum, with sales increasing 68% to $163 million, underpinned by growth in major markets like Germany, Italy, Spain, France, and the UK.
The product now stands as the top-selling BTKi worldwide, buoyed by a differentiated clinical profile and ongoing launches. TEVIMBRA (tislelizumab), BeOne’s anti-PD-1 antibody, also contributed meaningfully, with Q3 sales rising 17% year-over-year to $191 million.
Operational Efficiency and Investment in Pipeline Fuel Sustainable Growth
BeOne maintained a disciplined approach to spending while continuing to advance a broad pipeline. Total operating expenses grew by 11% to $1.05 billion (GAAP) in Q3, driven by targeted R&D and commercial investments. Importantly, selling, general, and administrative expenses fell to 38% of product sales—down from 46% a year earlier—showcasing greater efficiency as scale grows.
| Operating Expenses ($M) | Q3 2025 (GAAP) | Q3 2024 (GAAP) | % Change |
|---|---|---|---|
| Research & Development | 523.7 | 496.2 | +6% |
| Selling, General & Admin | 529.0 | 455.2 | +16% |
| Total Operating Expenses | 1,052.7 | 951.4 | +11% |
The company's pipeline progress is also noteworthy, with 47 abstracts accepted at the ASH Annual Meeting and multiple late-stage programs advancing, including sonrotoclax (BCL2 inhibitor) and BGB-16673 (BTK CDAC), which are set to fuel future milestones and value creation.
Cash Position and Free Cash Flow Hit All-Time Highs
Free cash flow in Q3 soared to $354 million, nearly seven times last year’s level, and cash on hand grew to over $4.1 billion. This positions BeOne well to support pipeline advancement, business development, and further commercial expansion without relying on outside capital.
| Cash & Liquidity Highlights | Sept 30, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash & Equivalents ($M) | 4,110.5 | 2,638.7 |
| Net Cash from Ops Q3 ($M) | 402.6 | 188.4 |
| Free Cash Flow Q3 ($M) | 354.5 | 54.7 |
Updated Guidance Reflects Ongoing Confidence
For the full year 2025, ONC expects revenue in the range of $5.1–$5.3 billion (raised from a prior low of $5.0B) and positive free cash flow, with gross margins in the mid- to high-80% range. Operating expense growth is expected to remain controlled, ensuring ongoing operating leverage as sales expand.
| Guidance | Previous | Current |
|---|---|---|
| Total Revenue ($B) | 5.0–5.3 | 5.1–5.3 |
| GAAP Operating Expenses ($B) | 4.1–4.4 | 4.1–4.3 |
| Gross Margin (%) | Mid-to-high 80s | Mid-to-high 80s |
| Free Cash Flow | Positive | Positive |
Pipeline Momentum: Clinical Advances and Regulatory Catalysts
In addition to strong financials, BeOne advanced a suite of late-stage clinical programs in oncology, inflammation, and immunology. Brukinsa’s recent regulatory wins, new formulations, and expanded approvals underpin the product’s commercial strength. Notable milestones in the coming quarters include pivotal readouts and regulatory submissions across core therapeutic areas such as marginal zone lymphoma (MZL), gastric cancer, CLL, and more.
Bottom Line: ONC’s Fundamentals and Pipeline Set the Stage for Long-Term Growth
With surging revenue, best-in-class BTKi market leadership, record cash generation, and a deep clinical pipeline, ONC is well positioned for further expansion. Investors and industry observers should watch for upcoming data readouts and regulatory milestones that could shape BeOne’s competitive landscape—and provide additional insights into the company’s evolving growth story.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI